Close-up on a video camera screen, a woman stares into the lens.

Stay up to date on COVID-19. Learn more

Filter
  • All years
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

October 2, 2024

The changing landscape of multiple myeloma – Toronto Star

September is Blood Cancer Awareness Month — an important time to spotlight the impact of blood cancers on the lives of Canadians. While many people are familiar with blood cancers like leukemia, they may not know that multiple myeloma is the second most prevalent blood cancer in Canada and is predicted[…]

Learn more

October 2, 2024

“I knew something was wrong”: A Terrebonne woman has to go back to the doctor six times to be diagnosed with blood cancer – Journal de Montreal (in French only)

A Terrebonne woman who had to go to the doctor six times before being diagnosed with blood cancer in 2013 is using her remission to raise awareness of this insidious disease and prevent other sufferers from being ignored. “I didn’t have a family doctor at the time and had to go[…]

Learn more

September 19, 2024

The Government of Canada introduces the Connected Care for Canadians Act 

On June 6, 2024, the Honourable Mark Holland, Minister of Health, introduced Bill C-72 the Connected Care for Canadians Act. This Act is about enabling Canadians to securely access their own health data, which will empower patient’s decision-making and improve the care they receive from health providers in Canada. This Act outlines[…]

Learn more

June 21, 2024

INESSS recommends including Tecvayli 

On June 5, 2024, the Institut national d’excellence en santé et en services sociaux (INESSS) formally recommended to the Minister that Tecvayli (teclistamab) be included in the list of medications at treatment centres for the treatment of patients with relapsed or refractory multiple myeloma, subject to specific conditions.   Read more here[…]

Learn more

June 20, 2024

Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma

To date, identifying high-risk SMM patients remains an important clinical need. In this study, we present the 3-dimensional telomere profiling as a structural biomarker capable of stratifying SMM patients as a function of genomic instability Read more… […]

Learn more

May 24, 2024

CCTG Recruiting for a Patient Representative Volunteer Role

The Canadian Cancer Trial Group (CCTG) is currently seeking applications for a Patient Representative for the Hematology Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. We encourage applications from all qualified candidates and will accommodate applicants’ needs throughout all stages of the recruitment and[…]

Learn more
1 2 3 12

Myeloma Canada updates

 

Filter
  • All years
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

September 24, 2024

Multiple myeloma: research update

Myeloma Canada, along with thousands from the global hematology community, had the privilege of following the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 – June 3) and the European Hematology Association (EHA) Hybrid Congress (June 13-16) to hear from leading myeloma experts about the latest progress in[…]

Learn more

September 19, 2024

Myeloma Canada at the CDA-AMC Symposium 2024

Canada’s Drug Agency (CDA-AMC) Symposium 2024 is a 3-day hybrid event in Ottawa (ON) that gathers leaders from across Canada with expertise in policy, industry, health technology assessment, patient advocacy, medicine, public health, and communications. Representing Myeloma Canada were Martine Elias – CEO; Jessy Ranger – Director, Health Policy, Advocacy[…]

Learn more

July 17, 2024

Letter to the Editor: The best of science and the worst of bureaucracy

We invite you to read our opinion letter, written by Jessy Ranger, Director, Patient  Programs, Health Policy & Advocacy at Myeloma Canada, and Christina Sit, Manager, Community and Strategic Partnerships at The Leukemia & Lymphoma Society of Canada, on the issues of access to treatment and care. As the country’s[…]

Learn more

July 16, 2024

Advocacy activities recap 2023

At first, engaging in advocacy initiatives involving government bodies, officials, drug agencies, and various stakeholders invested in improving the healthcare system or treatment accessibility may appear abstract or a little daunting. Nevertheless, numerous organizations, such as ours, are inherently suited to negotiate, influence and persuade those who have the authority[…]

Learn more

June 21, 2024

Martine Elias summarizes Real World Evidence (RWE) session at 2024 Myeloma Patients Europe Masterclass 

As proud members of Myeloma Patients Europe (MPe), Myeloma Canada attended – and presented at – MPe’s annual Masterclass this past May. The Masterclass is a one-and-a-half-day educational program designed to: increase the knowledge and skills of MPe’s members;  share the latest updates on myeloma and amyloidosis diagnosis, treatment and care;  discuss the[…]

Learn more

May 2, 2024

A round of applause for Martine and her new role! 

It is with great joy and pleasure that we announce the advancement of our well-regarded Executive Director, Martine Elias, to the distinguished position of CEO at Myeloma Canada.  Martine has been the driving force behind numerous achievements and advancements that have shaped Myeloma Canada into the leading organization it is today.[…]

Learn more
1 2 3 18